GE Healthcare launches Centricity Research, a new clinical research management solution

NewsGuard 100/100 Score

GE Healthcare, a global leader in healthcare information technology, today announced Centricity Research, a new clinical research management solution (CRMS). Centricity Research will help improve the efficiency and efficacy of clinical research studies, enterprise-wide, by driving better management of treatment plans, processes, and protocols while supporting research billing compliance.

“GE Healthcare is introducing a major leap forward in clinical research management”

Available today, Centricity Research is the industry's first enterprise-class clinical research management solution. Centricity Research helps institutions conducting clinical or translational research manage the growing complexity of research processes and compliance requirements. Centricity Research has robust functionality, built on the foundation of the currently available Centricity Patient Protocol Management solution, to support both the institutions' and researchers' efforts in achieving compliance, enhancing safety, increasing subject recruitment, and facilitating agency audits.

In addition, GE Healthcare has developed a strategic partnership with mdlogix, which developed its CRMS in collaboration with the Johns Hopkins University School of Medicine and other leading clinical research institutions.

"The enterprise deployment of CRMS at Johns Hopkins includes all departments in the School of Medicine," said Dr. Dan Ford, Vice-Dean of Clinical Research at the Johns Hopkins School of Medicine. "We have over 4,000 protocols currently in CRMS, with over 1,100 of those being active, and approximately 25% of those protocols using CRMS solely at the discretion of the researchers themselves because of the value they gain from the system. CRMS has helped us more efficiently manage the 30% increase we have achieved in the number of research studies conducted at the Johns Hopkins School of Medicine since 2007."

Centricity Research helps ensure adherence to protocols and maximizes clinical research dollars, while providing the foundation for the continuous improvement of research processes. The platform can integrate with a variety of existing institutional systems, including electronic IRB systems, EMR/EPR systems, and revenue cycle management (RCM) systems.

"GE Healthcare is introducing a major leap forward in clinical research management," said Jim Corrigan, Vice President and General Manager of GE Healthcare IT. "We're introducing a system that not only connects to our other Centricity offerings, but is pliable enough for today's market by easily integrating with the variety of other systems that institutions have in place."

"Having successfully deployed our enterprise CRMS at one of the leading research institutions in the nation, we are pleased to work with GE Healthcare to bring this enterprise solution to market," said Aaditya Goswami, CEO of mdlogix. "Our partnerships allow us to offer a solution unique in the domain for supporting clinical research compliance and maximizing efficiency. Centricity Research not only serves the needs of researchers and clinicians, but also those of billing staff and research administrators."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New research pinpoints key pathways in prostate cancer's vulnerability to ferroptosis